Technical Service Need help? Our team of experienced experts is here for you with full support.
AKA-46
Empagliflozin
Cat. No.
AKA-46
CAS No.
864070-44-0
MF
C23H27ClO7
MW
450.9
Empagliflozin is a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor.
Advanced Equipments & Extensive Production Expertise
Commercial Manufacturing
Stable Quality
Customization Supporting
Technical Service 
86-28-85159085 
info@aktin.com Technical Data
Description
Documents
Storage and Shipping
References
Product Name
Empagliflozin
CAS No.
864070-44-0
MF
C23H27ClO7
MW
450.9
Specification
99%
Research Area
Intermediate
Description
Empagliflozin is a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor. Packing: 1kg/bag; 25kg/drum or as request Availability: In Stock
Documents
Can't find the right version? Our team of experienced experts is here for you with full support.Contact Us
Storage and Shipping
Store in a cool & dry place, keep away from strong light and heat.
References
[1]. Grempler R, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes, Obesity & Metabolism. 2012 Jan;14(1):83-90. PMID: 21985634
[2]. Cheng ST, et al. The Effects of Empagliflozin, an SGLT2 Inhibitor, on Pancreatic β-Cell Mass and Glucose Homeostasis in Type 1 Diabetes. PloS One. 2016 Jan 25;11(1):e0147391. PMID: 26807719
[3]. Byrne NJ, et al. Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure. JACC. Basic to Translational Science. 2017 Aug;2(4):347-354.
[4]. Sakaeda T, et al. Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors. International Journal of Medical Sciences. 2018 Jun 13;15(9):937-943. PMID: 30008607
Related Products
* Some statements have not been evaluated by national authorities. * Some products are not intended to diagnose, treat, cure, or prevent any disease. * For literature supporting, please contact us directly.
